Search
TAK-475
go.drugbank.com/drugs/DB05317InvestigationalTAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.
N4-Hydroxycytidine
go.drugbank.com/drugs/DB15660Experimental[A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. … [A193014] It is orally bioavailable in mice and distributes into tissue before becoming the active 5’-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation
Synonyms: 4-N-Hydroxycytidine, N(4)-HydroxycytidineLoteprednol
go.drugbank.com/drugs/DB00873ApprovedInvestigationalWithdrawnLoteprednol is a corticosteroid. A more commonly used formulation of loteprednol is its ester, [loteprednol etabonate].
AVI-4065
go.drugbank.com/drugs/DB05620InvestigationalAVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc. … After phase II trials it was cancelled due to lack of potency. [L2917]
Ximelagatran
go.drugbank.com/drugs/DB04898ApprovedWithdrawnIn 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries … Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former.
Synonyms: ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(N'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetateGEM-231
go.drugbank.com/drugs/DB05798InvestigationalA monoclonal antibody combined with a toxic substance that is used treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. … Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells.
ALGRX 1207
go.drugbank.com/drugs/DB06482ExperimentalALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted. … ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel.
CP-122721
go.drugbank.com/drugs/DB05421ExperimentalCP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.